The FDA Has Accepted To Review Neurocrine Biosciences' New Drug Application For Ingrezza (Valbenazine) Oral Granules, With Prescription Drug User Fee Act Target Action Date Of April 30, 2024
Portfolio Pulse from Benzinga Newsdesk
The FDA has accepted to review Neurocrine Biosciences' New Drug Application for Ingrezza (Valbenazine) oral granules. The Prescription Drug User Fee Act target action date is April 30, 2024.
September 14, 2023 | 12:36 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Neurocrine Biosciences' New Drug Application for Ingrezza has been accepted for review by the FDA. This could potentially lead to a new revenue stream for the company if the drug is approved.
The FDA's acceptance to review Neurocrine Biosciences' New Drug Application for Ingrezza is a positive development for the company. If the drug is approved, it could potentially open up a new revenue stream for the company. This could have a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100